medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2005, Number 1

<< Back Next >>

Rev Mex Urol 2005; 65 (1)

Hyperactive bladder

Feria BG, Castillejos MRA, Arroyo KJC

Language: Spanish
References: 15
Page: 50-54
PDF size: 49.18 Kb.


ABSTRACT

It is an alteration, with predominance in women, the prevalence is directly proportional to the age of the patient, at more age, more probable to suffer it. The hyperactive bladder, can be presented associated with urinal incontinence, in minor percentage it is mixed with urinal incontinence caused by stress, but it can be alone. Its etiology can be due to abnormalities: of the urinal low tract, neurogenics, systemic, iatrogenics, psychological or dietetic habits. Clinical manifestations of the hyperactive bladder are: frequency, urgency, nycturia, and urinal incontinence, in addition to this the patient can suffer other alterations and as a whole, this forces him to change his social activity. A great variety of questionnaires exists about quality of life, nevertheless the physician refuses to apply them because it takes time and apparently they have small relevance. But without their use it turns out to be subjective to evaluate the therapeutic response. The physical exploration helps to discard other pathologies; general examination of urine, urocultive, blood chemistry in some cases with hormonal profile, etc. must be practiced in laboratory studies. The cabinet studies can be an ultrasound, cystography, cystoscospy and urodynamics. The therapeutics focuses to inhibiting the vesical contractions of the detrusor muscle, diminishing the vesical sensibility and miccional frequency. The physician is provided with a wide arsenal of antimuscarinic drugs to reach his purpose, with a variable grade of clinical improvement, side-effects and abandonment of the treatment.


REFERENCES

  1. Milsom I y cols. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760.

  2. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326(7394): 841.

  3. Debruyne FM y cols. Clinical and socioeconomic relevance of overactive bladder. Urology 2004; 63(Suppl. 1): 42.

  4. Wein A. Patophysiology and categorization of voiding dysfunction. Chapter 24. Campbell’s Urology Textbook. Saunders; 2002.

  5. Ouslander JG. Drug therapy: management of overactive bladder. NEJM 2004; 350: 786.

  6. Brown JS y cols. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48(7): 721.

  7. Abrams P y cols. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 2003; 61: 37.

  8. Van Kerrebroeck y cols. Tolterodine once-daily in treatment of the overactive bladder. Urology 2001; 58(5): 831.

  9. Zinner N y cols. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171(6): 2311.

  10. 10.López PP y cols. Trospium chloride for the treatment of detrusor inestability in children. J Urol 2003; 170(5): 1978.

  11. 11.Hatanaka T, Ukai M, Kobayashi S, Ikeda K, Sato S y cols. In vitro tissue selective profile of solifenacin succinate for urinary bladder over salivary gland in rats and mokeys. Poster 96. Paris, France: International Continence Society Meeting; 2004.

  12. 12.Hatanaka OA, Sato IK, Miyata K, Sasamata M. In vitro bladder selective profile of solifenacin succinate over salivary gland in mice and rats. Poster 297. Paris, France: International Continence Society Meeting; 2004.

  13. 13.Chapple CR, Cardoso L, Drogendijk T, Leiderdorp BV. Solifenacin reduced urgency in patients with overactive bladder. Poster 70. Paris, France: International Continence Society Meeting; 2004.

  14. 14.Cardoso L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I y cols. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172(5, parte 1 de 2): 1919.

  15. 15.Ahab F, Van Kerrebroeck P, Huang M, Ridder AM. Solifenacin associated with high persistence on therapy in long-term overactive bladder extension study. Poster 97. Paris, France: International Continence Society Meeting; 2004.




2020     |     www.medigraphic.com